RESEARCH & DEVELOPMENT

We began our journey by investing in research & development. Our efforts in research began in 2007 where we took up developing generics in the category of niche drugs to develop a diverse product portfolio spanning major therapeutic categories for global markets.

Our core strength lies in our ability to excel in developing generics and technologically complex products through focused teams in formulations, process chemistry and analytical development.We have the capability to deliver quality products within established timelines, at low costs and uncompromising quality.

Our research prowess can be exemplified by the fact that we are amongst the few manufacturers of drugs like Carmustine, Carglumic acid, Trientine HCl and Fomepizole in the world which are available at competitive prices than the innovator brand.

We are committed to improving patient lives in purposeful ways by providing safe and cost effective generic drugs. We strive to achieve leading innovation in generic medicine by developing a cost effective and focused product pipeline.

Our state of art R & D facility foot prints to almost 5200 Sq. M. Our team of experienced research scientists are constantly creating non infringing and economical process development for generic molecules with stringent quality standards. The dynamic and aggressive approach of our experienced scientists sets us apart from competitors making our capabilities unparalleled in the industry.

Our team of experts is constantly working to create a healthier society through innovation in healthcare.

We are currently developing molecules of various therapeutic categories like oncology, CNS, nephrology, hematology, cardiology and sexual dysfunction. We are now also open to taking up drug development projects from clients thus extending our research expertise and services to companies who would be interested. Our research team works in line with our business development team to generate innovative concepts and ideas, exploiting both market needs and synergies across therapeutic areas.

Along with focusing on developing new products, we continuously also monitor research efficiency.